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Medical Instrumentation—Perspective
ABSTRACT Visual prostheses are now entering the clinical 
marketplace. Such prostheses were originally targeted for 
patients suﬀ ering from blindness through retinitis pigmentosa 
(RP). However, in late July of this year, for the first time a 
patient was given a retinal implant in order to treat dry age-
related macular degeneration. Retinal implants are suitable 
solutions for diseases that attack photoreceptors but spare 
most of the remaining retinal neurons. For eye diseases that 
result in loss of retinal output, implants that interface with 
more central structures in the visual system are needed. The 
standard site for central visual prostheses under development 
is the visual cortex. This perspective discusses the technical 
and socioeconomic challenges faced by visual prostheses.
KEYWORDS neuroprostheses, vision, eye disease, restor-
ation of function, rehabilitation
1 Visual prosthesis development
1.1 The beginning
Technology intended to restore vision to blind people dates 
back to the late 1960s, when G. S. Brindley and W. S. Lewin of 
the University of Cambridge in the United Kingdom tested 
a visual cortical prosthesis on a 52-year old female blind pa-
tient. Brindley and Lewin sought to create visual sensations 
in this patient by electrically stimulating that part of the cere-
bral cortex known to represent visual information in sighted 
people. At that time, the occipital lobe of the human brain 
was known to be a center for the higher processing of visual 
signals, and it was known that electrical stimulation of this 
part of the visual system could evoke visual sensations called 
phosphenes; that is, the perception of spots of light, localized 
within the visual field. It was also known that such phos-
phenes could be evoked after years of blindness. The results 
obtained with the ﬁ rst visual prosthesis were so encouraging 
that Brindley and Lewin predicted in the conclusions section 
of their paper that improvements to their prototype should 
“pe rmit blind patients not only to avoid obstacles when walk-
ing, but to read print or handwriting, perhaps at speeds com-
parable with those habitual among sighted people.” 
1.2 Waxing and waning
The ﬁ eld of visual prostheses has waxed and waned over the 
decades since this pioneering effort, and its history might 
thus serve as a case study in how challenging the develop-
ment of medical technology can be. The failure of Brindley 
and Lewin to deliver on the bold prediction made in their 
conclusions section had a dampening effect on enthusiasm 
for the ﬁ eld, and we should learn from this. A developer of 
medical technology needs to tread a fine line between pro-
moting a product enthusiastically in order to garner the fi-
nancial support needed to bring it to market and avoiding the 
damaging effect of overstating its likely short-term impact. 
One needs to become adept at defining realistic milestones 
and, at the same time, portraying the larger signiﬁ cant long-
term impact. The investment community is attuned to the 
course of technological development. The patient population 
is hungry for therapies and is therefore both more susceptible 
to accepting overstated claims and less forgiving when the 
outcomes fall short of expectations. Today, nearly half a cen-
tury later, the visual capacities that Brindley and Lewin pre-
dicted would be soon provided by a visual prosthesis seem 
distant. Current visual prostheses fall far short of providing 
the level of visual performance proposed, and many techni-
cal challenges, unappreciated by Brindley and Lewin, remain 
to be addressed.
1.3 Recent developments
We are currently experiencing an upswing in interest in visu-
al prostheses, following some major recent successes. Retinal 
implants, developed by Second Sight in the US and Re tinal 
Implant AG in Germany, are now available as clinical prod-
ucts. Initially targeted to patients rendered blind through 
retinitis pigmentosa (RP), in July of 2015, a retinal implant 
was for the first time given to a patient suffering from dry 
age-related macular degeneration (AMD): 80-year old Ray 
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Flynn, at the Manchester Royal Eye Hospital in the United 
Kingdom. Both RP and AMD are eye diseases that lead to 
blindness through the loss of photoreceptors. The incidence 
of the former disease is signiﬁ cantly lower than AMD and af-
fects a younger group of patients. It made good sense there-
fore to target patients with RP as the initial recipients for a 
retinal implant, leaving those with AMD to follow. Certainly, 
for investors, the potential for a technology to be applied to 
the population of AMD patients is enticing, since this popu-
lation is already large and is sure to grow significantly in 
coming decades as the populations of developed countries 
age. Indeed, the potential to apply new technologies to AMD 
patients may be essential. The cost of developing technology 
to interface with the central nervous system, of which the 
retina is a displaced part, is immense and unthinkable from 
a commercial perspective without the prospect of it being of 
use to a substantial patient population.
2 Retinal and visual cortical prostheses
There are a number of reasons why retinal prostheses have 
reached the clinic ahead of visual prostheses that interface 
with the visual cortex or other areas of the visual system. 
Anyone considered a candidate for a visual prosthesis today 
must be blind in both eyes and must hope for just partial 
restoration of monocular vision. Partial restoration can be 
accomplished with a single retinal implant, while a visual 
cortical prosthesis would likely require two implants, one 
for each hemisphere, since the left visual ﬁ eld is represented 
in the right visual cortex and the right visual ﬁ eld is repre-
sented in the left visual cortex. Another advantage of the reti-
nal implant is that the full visual ﬁ eld is exposed across the 
retinal surface. For the visual cortical prosthesis, a signiﬁ cant 
fraction of the visual ﬁ eld is not represented on the brain sur-
face but is instead buried in sulci (infoldings of the cerebral 
cortex), making it more difﬁ cult to access for electrical stimu-
lation. A third advantage of the retinal implant follows from 
the fact that these implants are more resistant to tissue rejec-
tion than cortical implants are. Adverse tissue responses are 
greater when an implant damages blood vessels. The retina 
has two blood supplies: the choroid and the retinal circula-
tion. Both varieties of retinal prosthesis—the subretinal im-
plant, which is positioned where degenerated photoreceptors 
once resided, and the epiretinal implant, which is situated 
adjacent to the retina’s inner limiting membrane—make no 
contact with blood vessels. In contrast, visual cortical pros-
theses that employ penetrating electrodes invade the rich 
capillary bed and larger blood vessels that feed the cerebral 
cortex. Hence cortical implants are more prone to generate a 
signiﬁ cant adverse tissue response. 
A number of the technological challenges that affect vi-
sual prostheses are the same as those affecting many other 
brain implants: for example, how to minimize damage to 
tissue and electrodes through implantation and electrical 
stimulation; how to protect electronics from the electrolyte 
environment of the brain; how to better match the mechani-
cal properties of the implant, which is generally rigid, with 
the mechanical properties of the brain, which is soft; how to 
transfer power to and signals to and from the implant; how 
to ensure that the implant does not interfere with the ﬂ ow of 
nutrients to brain cells; how to minimize the heating of tissue 
during stimulation; and so forth. There are also some chal-
lenges that are speciﬁ c to visual prostheses. Accomplishing 
Brindley and Lewin’s goal of creating a visual prosthesis per-
mitting a patient to read at a speed comparable to a sighted 
person would require considerably more electrodes than are 
available in current retinal prostheses. In fact, accomplishing 
this goal will likely require the development of electrodes 
made of novel materials, which have yet to obtain regulatory 
sanction. A number of investigators have studied materials 
with a superior charge-transfer capacity to standard plati-
num electrodes and, as electrode-tip size decreases in order 
to achieve the goal of higher electrode density, one or more of 
these materials is likely to be essential. 
It is with regard to the goal of attaining good reading per-
formance that the advantage shifts from the retinal prosthesis 
to the visual cortical prosthesis. The fact that the representa-
tion of central vision is magniﬁ ed in the visual cortex relative 
to peripheral vision means that good acuity is attainable with 
reasonable electrode spacing. For the retinal implant, the 
task of stimulating the central retina is daunting. The retinal 
ganglion cells—the output cells—are packed tightly, stacked 
and displaced from the fovea. It is hard to imagine how these 
important drivers of central vision, essential for the detailed 
viewing of objects and for reading, can be effectively driven 
with a retinal prosthesis. 
Visual cortical prostheses have one other important advan-
tage: They offer a solution to restoring vision to those ren-
dered blind through the loss of retinal ganglion cells—such 
as would occur in the event of eye loss or with the disease 
glaucoma, which is the leading cause of incurable blindness 
in the world and the cause of blindness for Brindley and 
Lewin’s patient. However, technical challenges are perhaps 
not the major obstacles to the development of visual prosthe-
ses. There are many social and economic factors that poten-
tially stand in the way of success and it is prudent to consider 
them also. 
2.1 Economic considerations
The economics of visual prostheses raises concern about 
the distribution of medical care. It is perhaps too early in 
the development cycle to put a price on the cost of a visual 
prosthesis, but one imagines that the same kinds of concern 
that have been raised for the implementation of cochlear and 
deep brain stimulation (DBS) implants will apply. Both of 
these technologies have seen an uneven distribution of appli-
cation across the world’s population, reﬂ ecting in a large part 
the uneven distribution of medical care generally. Europe, 
North America, and developed Asia and Oceania have been 
early beneﬁ ciaries. Rapidly developing countries like China 
are also beneﬁ ting, often ﬁ rst from donation units with the 
expectation that a commercial market will follow. Within the 
developed world, inequity in delivery also exists. In a study 
of more than 500 000 Medicare beneﬁ ciaries with Parkinson’s 
disease in the US, it was found that men were more likely to 
receive DBS implants than women and that white patients 
290
Medical Instrumentation—PerspectiveResearch
Engineering  Volume 1 · Issue 3 · September 2015  www.engineering.org.cn
were more likely to receive them than African-American or 
Asian patients. 
There is also the issue of cost effectiveness. Both the co-
chlear and DBS implants have been the subject of studies 
seeking to evaluate the beneﬁ t of these treatments in relation 
to cost. Placing a monetary value on the restoration of vision, 
hearing, or improved motor performance is obviously not 
something that will be without disagreement, but it is neces-
sary if we are to evaluate the effectiveness of brain-implant 
technology. Studies seeking to evaluate the effectiveness of 
DBS implants for Parkinson’s disease have demonstrated im-
provements in quality of life for patients. Unfortunately, as 
far as I have been able to tell, no economist has been involved 
in the assessment of outcomes, so one must question the rigor 
with which economic value has been determined. Another 
problem is that there are many measures of quality of life in 
existence. The World Health Organization (WHO) has WHO 
Quality of Life-BREF (WHOQOL-BREF), the US Center for 
Disease Control has Health-Related Quality of Life (HRQOL), 
and the US HealthyPeople.gov has HRQoL. There are also 
various measures crafted for specific medical subgroups: 
① the Eastern Cooperative Oncology Group’s metric, ② the 
New York Heart Association scale, and ③ the stroke-speciﬁ c 
quality of life (SS-QOL) measure. For auditory performance, 
there is the Glasgow Beneﬁ t Inventory. So, in summary, there 
is no generally accepted measure that could be used to assess 
how much beneﬁ t a visual prosthesis would provide a patient 
and no economically justifiable means thus far established 
to assign a monetary value to that beneﬁ t, against which the 
cost of the treatment could be evaluated.
2.2 Societal considerations
Another somewhat surprising challenge affecting medical 
technology has come from the patient population that the 
technology is intended to assist. Hearing impaired groups 
opposed the cochlear implant, fearing that this technology 
would splinter their community. Hearing impaired people 
are drawn together because of their disability. Sign language 
and lip reading are well-developed skills that permit easy 
communication, bonding, and the formation of a commu-
nity. If participants of the community are to be removed and 
introduced to the broader hearing population, it is natural 
that those fearing abandonment may resist the technology 
that heralds the change. If a technology is revolutionary, it 
is disruptive; and this comes at a cost. There will be winners 
and losers, and it is not always easy to predict who will view 
themselves in which group.
Within this context, one should also look to resistance from 
the scientific community. None are better able to articulate 
the weaknesses of a new technology than those working in 
that ﬁ eld or in one closely related to it. To many visual neu-
roscientists, visual prostheses seem naively simplistic. When 
Brindley and Lewin built their visual cortical prosthesis, it 
was known that the amount of cortical tissue devoted to rep-
resenting a region of the central visual ﬁ eld was dispropor-
tionately more than the amount of cortical tissue devoted to 
representing an equal area of the peripheral visual ﬁ eld. At 
that time, our understanding of the representation of infor-
mation at the cellular level in the visual cortex had recently 
been advanced significantly by the work of future Nobel 
Laureates David  Hubel and Torsten Wiesel. This knowledge 
was not incorporated into the prosthetic design, presumably 
because at that time it seemed to be unnecessarily detailed. 
Today, our understanding of how visual information is repre-
sented in the cerebral cortex is considerably more complex; it 
involves many distinct cortical areas, a vast array of distinct 
cell-types, and many recurrent connections between cortical 
areas and between cortical and sub-cortical areas. The de-
signers of modern visual cortical prostheses, while producing 
devices that are more sophisticated than that of Brindley and 
Lewin, hardly seek to embrace our current knowledge base, 
and are probably right not to do so. The DBS implant for Par-
kinson’s disease has been successful, in spite of researchers 
having a poor understanding of how it works, and in spite 
of it having been developed with minimal application of our 
understanding of the neural pathways that it affects. How-
ever, this approach will garner considerable resistance from 
members of the neuroscience community, who naturally feel 
that their discoveries should be embraced and factored into 
technologies to restore vision. The challenge for technology 
developers is to explain why much of our current knowledge 
base is at a level of detail for which current technology has 
no application. It should also be considered that knowledge 
evolves. Our understanding today of the visual cortex is 
richer than it was in the 1960s when Brindley and Lewin de-
veloped their visual prosthesis. Although our understanding 
will be better ﬁ ve years from now, blind patients have a right 
to expect us to develop technologies now that will improve 
their lives, even if these technologies are imperfect. The 
neuroscience of today may help to make vision restoration 
in 2115 better, but it should not inhibit the development of to-
day’s technology.
3 Brain plasticity and visual rehabilitation
Whatever visual prosthesis is developed, it is well under-
stood that rehabilitation training on an individual-patient ba-
sis will be necessary in order to maximize its impact. When 
Brindley and Lewin developed their visual prosthesis, it was 
widely believed that there was minimal plasticity in adult 
human brains. However, the passage of time has changed our 
understanding of the visual cortex and brain plasticity sig-
niﬁ cantly, and plasticity of the adult brain has been well es-
tablished. Rehabilitation from stroke, for example, is founded 
on this principle. In retrospect, it is hard to imagine how the 
capacity for change in the adult brain could have been ques-
tioned; for example, while it is harder to learn a foreign lan-
guage as an adult than as a child, it is possible. However, this 
disparity for learning between adults and children should 
not be forgotten when we consider how difficult it may be 
for recipients of visual prostheses in adulthood to learn how 
to make sense of the impoverished signals the prostheses 
provide, in comparison to those provided by an intact and 
functioning visual system. A number of groups working in 
the ﬁ eld of visual prostheses have already given considerable 
thought to training protocols. These are an important compo-
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nent of the development of this technology that researchers 
are apt to overlook.
4 Concluding remarks
In sum mary, we may ﬁ nally be at the true dawn of the era of 
visual prostheses, after a number of false dawns. Many chal-
lenges remain that must be addressed in order to ensure that 
the current situation is not another false dawn. While the 
engineering community remains focused on addressing the 
technological problems, we should remain vigilant in ensur-
ing that expectations among the patient population are not 
raised to an unrealistic level. In addition, it is also essential 
that developers consider the path to success, which requires 
thought about the initial patient population to target and 
the economic beneﬁ t that would accrue from the technology. 
The development of sound outcome measures that would be 
considered valid by a group of economists would be a useful 
ﬁ rst step. Also, many have noted that with medical technol-
ogy it is never too early to consider what steps one must take 
to obtain regulatory approval. It is a mistake to believe that 
regulatory agencies like the Food and Drug Administration 
(FDA) in the US exist to hinder the advance of medical tech-
nology. Their role is to serve the population, and this role 
has two components: to protect the population, and to bring 
therapies to patients as quickly as possible. Consultation with 
the FDA or equivalent agencies in other jurisdictions early in 
the design process would be prudent, as these agencies can 
advise developers on how best to demonstrate the efficacy 
and safety of a new technology.
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